Azoulay Daniel, Linhares Marcello M, Huguet Emmanuel, Delvart Valérie, Castaing Denis, Adam René, Ichai Philippe, Saliba Faouzi, Lemoine Antoinette, Samuel Didier, Bismuth Henri
Hepatobiliary Center, Hôspital Paul Brousse, Assitance Publique-Hôpitaux de Paris and Université Paris Sud, Villejuif, France.
Ann Surg. 2002 Dec;236(6):713-21; discussion 721. doi: 10.1097/01.SLA.0000036264.66247.65.
To determine the patient factors affecting patient outcome of first liver retransplantation at a single center to help in the decision process for retransplantation.
Given the critical organ shortage, one of the most controversial questions is whether hepatic retransplantation, the only chance of survival for patients with a failing first organ, should be offered liberally despite its greater cost, worse survival, and the inevitable denial of access to primary transplantation to other patients due to the depletion of an already-limited organ supply. The authors' experience of 139 consecutive retransplantations was reviewed to evaluate the results of retransplantation and to identify the factors that could improve the results.
From 1986 to 2000, 1,038 patients underwent only one liver transplant and 139 patients underwent a first retransplant at the authors' center (first retransplantation rate = 12%). Multivariate analysis was performed to identify variables, excluding intraoperative and donor variables, associated with graft and patient long-term survival following first retransplantation. Lengths of hospital and intensive care unit stay and hospital charges incurred during the transplantation admissions were compared for retransplanted patients and primary-transplant patients.
One-year, 5-year, and 10-year graft and patient survival rates following retransplantation were 54.0%, 42.5%, 36.8% and 61.2%, 53.7%, and 50.1%, respectively. These percentages were significantly less than those following a single hepatic transplantation at the authors' center during the same period (82.3%, 72.1%, and 66.9%, respectively). On multivariate analysis, three patient variables were significantly associated with a poorer patient outcome: urgency of retransplantation (excluding primary nonfunction), age, and creatinine. Primary nonfunction as an indication for retransplantation, total bilirubin, and factor II level were associated with a better prognosis. The final model was highly predictive of survival: according to the combination of the factors affecting outcome, 5-year patient survival rates varied from 15% to 83%. Retransplant patients had significantly longer hospital and intensive care unit stays and accumulated significantly higher total hospital charges than those receiving only one transplant. CONCLUSIONS These data confirm the utility of retransplantation in the elective situation. In the emergency setting, retransplantation should be used with discretion, and it should be avoided in subgroups of patients with little chance of success.
确定影响单中心首次肝再移植患者预后的因素,以辅助再移植决策过程。
鉴于关键器官短缺,最具争议的问题之一是,尽管肝再移植成本更高、生存率更低,且会因有限器官供应的耗尽而不可避免地导致其他患者无法获得初次移植机会,但对于初次移植器官功能衰竭的患者而言,这是唯一的生存机会,是否应广泛提供肝再移植。回顾了作者连续139例再移植的经验,以评估再移植结果并确定可改善结果的因素。
1986年至2000年,作者所在中心有1038例患者仅接受了一次肝移植,139例患者接受了首次再移植(首次再移植率=12%)。进行多变量分析以确定与首次再移植后移植物和患者长期生存相关的变量,排除术中及供体变量。比较了再移植患者与初次移植患者的住院时间、重症监护病房停留时间以及移植入院期间产生的住院费用。
再移植后1年、5年和10年的移植物和患者生存率分别为54.0%、42.5%、36.8%和61.2%、53.7%、50.1%。这些百分比显著低于同期作者所在中心单次肝移植后的生存率(分别为82.3%、72.1%和66.9%)。多变量分析显示,三个患者变量与较差的患者预后显著相关:再移植的紧迫性(不包括原发性无功能)、年龄和肌酐。以原发性无功能作为再移植指征、总胆红素和因子II水平与较好的预后相关。最终模型对生存率具有高度预测性:根据影响预后的因素组合,5年患者生存率在15%至83%之间变化。再移植患者的住院时间和重症监护病房停留时间显著更长,累计住院总费用显著高于仅接受一次移植的患者。结论这些数据证实了在择期情况下再移植的实用性。在急诊情况下,应谨慎使用再移植,对于成功机会渺茫的患者亚组应避免进行再移植。